In: Cowie CC, Casagrande SS, Menke A, Cissell MA, Eberhardt MS, Meigs JB, Gregg EW, Knowler WC, Barrett-Connor E, Becker DJ, Brancati FL, Boyko EJ, Herman WH, Howard BV, Narayan KMV, Rewers M, Fradkin JE, editors. Diabetes in America. 3rd edition. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases (US); 2018 Aug. CHAPTER 17.
PMID:33651551
Clinical and biochemical characteristics and analysis of risk factors for euglycaemic diabetic ketoacidosis in type 2 diabetic individuals treated with SGLT2 inhibitors: A review of 72 cases over a 4.5-year period.
SGLT2 inhibitors and metformin: Dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes.
Donnan K, Segar L.
Eur J Pharmacol. 2019 Mar 5;846:23-29. doi: 10.1016/j.ejphar.2019.01.002. Epub 2019 Jan 11.
PMID:30639796
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor- and Metformin-Associated Euglycemic Diabetic Ketoacidosis and Lactic Acidosis Leading to Refractory Acute Kidney Injury: Successful Management With Hemodialysis.
Yoshida N, Tanaka T, Suzuki Y, Sakurai H, Takahashi S, Hitaka M, Ishii S, Okuda J, Yamazaki K, Ohashi Y.
Cureus. 2025 Mar 22;17(3):e80989. doi: 10.7759/cureus.80989. eCollection 2025 Mar.